Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology/GOG study

(2015) James S. Ferriss et al.   GYNECOLOGIC ONCOLOGY

Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients

(2015) Katherine C. Fuh et al.   GYNECOLOGIC ONCOLOGY

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support

(2015) Joseph Ciccolini et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: The Kaohsiung Chang Gung experience

(2015) Ching-Fen Hu et al.   Taiwanese Journal of Obstetrics & Gynecology

Transient Antiangiogenic Treatment Improves Delivery of Cytotoxic Compounds and Therapeutic Outcome in Lung Cancer

(2014) S. Chatterjee et al.   CANCER RESEARCH

Translational Impact of Nanoparticle-Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

(2014) E. Pham et al.   CLINICAL CANCER RESEARCH

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

(2014) Eric Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy

(2014) David E. Piccioni et al.   NEURO-ONCOLOGY

Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease

(2013) B. J. Monk et al.   ANNALS OF ONCOLOGY

Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake

(2013) M. Arjaans et al.   CANCER RESEARCH

Combining two strategies to improve perfusion and drug delivery in solid tumors

(2013) T. Stylianopoulos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antiangiogenic Therapies: Going beyond Their Limits

(2013) L. Moserle et al.   Cancer Discovery

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner

(2012) Vikash P. Chauhan et al.   Nature Nanotechnology

Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

(2012) Y. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

(2012) S. J. Conley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)

(2011) Gordon John Sampson Rustin et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE